Cohort study for patients with aggressive lymphoma
A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
This study looks at patients with aggressive lymphoma to see how well standard treatments work and how the disease changes over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 20 Years to 90 Years |
| Sex | All |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Trial ID | NCT03117036 on ClinicalTrials.gov |
What this trial studies
This observational cohort study enrolls patients diagnosed with aggressive forms of lymphoma, including Hodgkin and non-Hodgkin lymphomas. Participants will receive treatment according to standard clinical practices at the institution, and their disease status, response to therapy, and survival will be monitored throughout the study. Blood samples will be collected to analyze serum and cell-free DNA, providing insights into the disease's progression and treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20 and older with pathologically diagnosed Hodgkin or non-Hodgkin lymphomas who require systemic chemotherapy.
Not a fit: Patients with myeloid malignancies, multiple myeloma, or those not requiring systemic chemotherapy with curative intent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lymphoma treatment responses and improve patient outcomes.
How similar studies have performed: Other studies have shown success in utilizing similar cohort approaches to understand lymphoma treatment outcomes, indicating this methodology is well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 2. 20 years 3. Patients requiring systemic chemotherapy with curative intent 4. Written informed consent Exclusion Criteria: 1. Myeloid malignancy 2. Multiple myeloma 3. Patients do not require systemic chemotherapy with curative intent
Where this trial is running
Seoul
- Samsung Medical Center — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Seok Jin Kim, MD, PhD — Samsung Medical Center
- Study coordinator: Seok Jin Kim, MD, PhD
- Email: kstwoh@skku.edu
- Phone: +82234101766
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.